Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BGM Group Ltd. (BGM)
Chengdu, CN
Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Qilian Shan Licorice Extract, serving as a raw material for pharmaceutical firms to produce conventional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient utilized by medical preparers for crafting compound licorice oral solutions. BGM also provides Qilian Shan oxytetracycline tablets, formulated to prevent and treat a range of ailments in poultry (chickens, turkeys), livestock (cattle, swine), and humans, in addition to Qilian Shan oxytetracycline APIs for use by pharmaceutical manufacturers. Beyond APIs, the company produces TCM derivatives such as Ahan antibacterial paste, which is designed for managing stubborn chronic skin conditions. Its diverse offerings also encompass heparin products, including heparin sodium preparations essential for pharmaceutical companies developing treatments for cardiovascular and cerebrovascular diseases, as well as hemodialysis applications. Furthermore, BGM supplies natural food products like Zhu Xiaochang sausage casings for culinary use. In the agricultural sector, it offers Xiongguan organic fertilizers, which enhance crop yields, improve soil chemical characteristics, and alleviate compaction, alongside Xiongguan organic-inorganic compound fertilizers engineered to promote superior plant development. Established in 2019, the company operated as Qilian International Holding Group Limited until adopting its current name, BGM Group Ltd, in October 2024.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.15% | +12.08% | +8.26% | -71.42% | -95.88% | -91.40% | -97.63% | -94.23% | -94.23% | -94.23% | -94.23% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-46.0%
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+81.5% ★
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+1.6% Q1'25: -28.5%
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-1.4% Q1'25: -15.6%
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-1.4% Q1'25: -3.1%
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0%
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× ★ Q1'25: -0.25×
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
No beneficial ownership filings recorded.
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 47.0K -198.0 (-0.4%) | 14.2K -159.8K (-91.8%) | 0.15% -0.001 pp | 0.00% +0.000 pp | USD10.26 -97.1% | 4 qtrs — |
| 2 | STATE STREET CORP | 46.5K -2.6K (-5.3%) | 14.1K -167.3K (-92.2%) | 0.15% -0.008 pp | 0.00% +0.000 pp | USD9.94 -97.0% | 3 qtrs — |
| 3 | HRT FINANCIAL LP | 48.2K +48.2K (+100.0%) | 14.0K +14.0K (+100.0%) | 0.15% +0.152 pp | 0.00% +0.000 pp | USD0.30 +0.0% | 1 qtrs NEW |
| 4 | TWO SIGMA SECURITIES, LLC | 16.1K +16.1K (+100.0%) | 4.9K +4.9K (+100.0%) | 0.05% +0.051 pp | 0.00% +0.001 pp | USD0.30 +0.0% | 1 qtrs NEW |
| 5 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 15.7K +15.7K (+100.0%) | 4.8K +4.8K (+100.0%) | 0.05% +0.050 pp | 0.00% +0.000 pp | USD0.30 +0.0% | 1 qtrs NEW |
| 6 | XTX TOPCO LTD | 11.4K +11.4K (+100.0%) | 3.5K +3.5K (+100.0%) | 0.04% +0.036 pp | 0.00% +0.000 pp | USD0.30 +0.0% | 1 qtrs NEW |
| 7 | GSA CAPITAL PARTNERS LLP | 10.2K +10.2K (+100.0%) | 3.0K +3.0K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.000 pp | USD0.30 +0.0% | 1 qtrs NEW |
| 8 | TOWER RESEARCH CAPITAL LLC (TRC) | 8.2K +7.7K (+1,629.3%) | 2.5K +732.0 (+41.8%) | 0.03% +0.025 pp | 0.00% +0.000 pp | USD0.50 -40.0% | 7 qtrs — |
| 9 | ROYAL BANK OF CANADA | 2.0K +930.0 (+86.4%) | 1.0K -3.0K (-75.0%) | 0.01% +0.003 pp | 0.00% +0.000 pp | USD2.12 -85.8% | 4 qtrs — |
| 10 | JPMORGAN CHASE & CO | 2.0K +229.0 (+13.1%) | 882.00 -5.6K (-86.4%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD3.30 -90.9% | 2 qtrs — |
| 11 | UBS GROUP AG | 2.0K -934.0 (-32.4%) | 590.00 -10.1K (-94.5%) | 0.01% -0.003 pp | 0.00% +0.000 pp | USD10.51 -97.1% | 8 qtrs — |
| 12 | MORGAN STANLEY | 200.00 +200.0 (+100.0%) | 61.00 +61.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD0.30 +0.0% | 1 qtrs NEW |
| 13 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 5.00 +5.0 (+100.0%) | 2.00 +2.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.20 +50.0% | 1 qtrs NEW |
| 14 | SBI SECURITIES CO., LTD. | 3.00 +3.0 (+100.0%) | 1.00 +1.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 1 qtrs NEW |
| 15 | BANK OF AMERICA CORP /DE/ | — -5.0 (-100.0%) | — -18.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 16 | INVESCO LTD. | — -132.5K (-100.0%) | — -488.9K (-100.0%) | 0.00% -0.419 pp | 0.00% 0.000 pp | USD— | 5 qtrs SOLD |
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Fidelity Nasdaq Composite Index ETF ONEQ | 0.00% | 20.8K | 0.21% |
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | Lou Zefei | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-04-13 | ZHANG LIN (Henry) | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-31 | ren yuehua | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-31 | ZHAI Yaxuan | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-31 | XU WAIHUA | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhanchang Xin | Chairman of the Board, President, Chief Operating Officer & Chief Scientific Officer | 17.9K | male |
| Chen Xin | CEO, VP of Duxiaobao Management Committee & Chairman | — | male |
| Yaxuan Zhai | Chief Financial Officer | — | female |
| Yuqing Li | Co-Chief Executive Officer | — | male |
| Zhao Huandi | Co-Chief Executive Officer & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BGM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
